web.oncoletter.chweb.oncoletter.ch/files/cto_layout/Kongressdateien/ASCO-GI 2017/C04... · Presented by-Hans-Joachim Schmoll p = 0,085 (sign. < 0.1) 0,16 2017 Gastrointestinal Cancers
Documents
SABCS 2016web.oncoletter.ch/files/cto_layout/Kongressdateien... · 2016. 12. 10. · First study with CellSearch@, N=118 pts (REMAGUS02) No significant association between CTC detection
web.oncoletter.chweb.oncoletter.ch/files/cto_layout/Kongressdateien/ASH2014/ASH2014_80.pdf · Tx to at least one prior regumen and then developed PO s 60 days corn*tTtg their last
Translocation (11;14)(q13;q32) and preferential ...with MCL is t(11;14)(q13;q32), but other variants such as t(11;22) have also been described [23]. Deletion 6q15 and monosomy 13 are
Slide 2 / 17web.oncoletter.ch/files/cto_layout/Kongressdateien/SABCS2015/S5-0… · slide 9 / 17 slide 10 / 17 page 5. undefined s5-05 trastuzumab emtansine improves overall survival
oncoletterweb.oncoletter.ch/files/cto_layout/Kongressdateien/... · Cycle 2 Cvcle3-6 Cycle7-24 Follow-Up Daratumumab infusions (First infusion includes pre-dose the before) Lenalidomide
Slide 2 / 23 - web.oncoletter.chweb.oncoletter.ch/files/cto_layout/Kongressdateien/SABCS2015/S4-0… · slide 1 / 23 slide 2 / 23 page 1. undefined s4-04 lobular carcinoma in situ
Pretreatment with Prasugrel in Non ST-Segment Elevation ...web.oncoletter.ch/files/cto_layout/Kongressdateien/ECCO ESMO 201… · sponsored by Daiichi Sankyo and Eli Lilly, and was
SABCS 2013 - oncoletterweb.oncoletter.ch/.../Kongressdateien/SABCS2013/S3-06.pdf · 2013. 12. 13. · Dr. Schnitt: Nothing to disclose. 2013 SAN ANTONIO BREAST CANCER SYMPOSIUM .
oncoletterweb.oncoletter.ch/files/cto_layout/Kongressdateien/ASCO... · 2017. 1. 21. · PRODIGE OE RECHERC*e GEMOX vs surveillance following surgery of localized biliary tract cancer:
web.oncoletter.chweb.oncoletter.ch/files/cto_layout/Kongressdateien/MWS... · · 2015-09-24Common Themes Does patient need treatment If yes, are they fit or frail (2 drugs) Should
SABCS 2013 - oncoletterweb.oncoletter.ch/files/cto_layout/Kongressdateien/... · 'One P30+DOC randomized patient received RAM DOC n Cycle I only therefore is included in the RAM DOC
Slide 2 / 28web.oncoletter.ch/files/cto_layout/Kongressdateien/SABCS2015/S6-0… · slide 1 / 28 slide 2 / 28 page 1. undefined s6-04 patient-reported outcome (pro) results, nrg oncology/nsabp
Linfomas de Células B iniciales e indolentes · 2013. 7. 11. · MCL Classical MCL t(11;14) Cyclin D1 Long Latency Periods in the Progression of MCL Christian B et al JCO 2010, ASH
Slide 2 / 20 - oncoletterweb.oncoletter.ch/files/cto_layout/Kongressdateien/SABCS2015/S5-07.… · NEGATIVE ADVANCED BREAST CANCER ENROLLED IN KEYNOTE-028 Speaker: Hope S Rugo Slide
Amylose ALaihemato.cluster013.ovh.net/AIH/documents/Cours DES/DES...Amylose AL 90% prolifération plasmocytaire IgG, IgA, caînes légères seules (50% des cas) Translocation t(11;14)
SABCS 2016web.oncoletter.ch/files/cto_layout/Kongressdateien/SABCS2016/SLID… · Double-blind Concordance Study of Breast Cancer Recommendations Between Manipal Multidisc* Tumor
web.oncoletter.chweb.oncoletter.ch/files/cto_layout/Kongressdateien/ASCO-GI 2017/C05... · Rapido trial, results awaited Locally advanced Rectal Cancer International randomized multicentre
![Translocation (11;14)(q13;q32) and preferential ...with MCL is t(11;14)(q13;q32), but other variants such as t(11;22) have also been described [23]. Deletion 6q15 and monosomy 13 are](https://static.documents.pub/doc/80x56/6050220ab1a6ff33e8485b4d/translocation-1114q13q32-and-preferential-with-mcl-is-t1114q13q32.jpg)
